Cargando…
Disease activity following pregnancy-related discontinuation of natalizumab in MS
OBJECTIVE: To investigate disease activity and disability progression following pregnancy-related discontinuation of natalizumab (NTZ) in patients with relapsing-remitting MS. METHODS: A retrospective cohort study of clinical and radiologic data in patients who discontinued NTZ for pregnancy-related...
Autores principales: | Kleerekooper, Iris, van Kempen, Zoé L.E., Leurs, Cyra E., Dekker, Iris, Rispens, Theo, Lissenberg-Witte, Birgit I., van Munster, Caspar E.P., de Jong, Brigit A., van Oosten, Bob W., Uitdehaag, Bernard M.J., Wattjes, Mike P., Killestein, Joep |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5778770/ https://www.ncbi.nlm.nih.gov/pubmed/29379823 http://dx.doi.org/10.1212/NXI.0000000000000424 |
Ejemplares similares
-
Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients
por: Leurs, Cyra E, et al.
Publicado: (2017) -
The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing
por: van Kempen, Zoé LE, et al.
Publicado: (2017) -
Natalizumab concentrations during pregnancy in three patients with multiple sclerosis
por: Toorop, Alyssa A, et al.
Publicado: (2021) -
Response to “Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing”
por: van Kempen, Zoé LE, et al.
Publicado: (2017) -
Infusion-related events during natalizumab: No need for post-infusion monitoring
por: Loonstra, Floor C, et al.
Publicado: (2019)